Kornimate/medical-research-clean huggingface dataset:
impact of acetazolamide in reducing referred postoperative pain

Conditions: Prostate Cancer; Men

Summary: robotic assisted laparoscopic prostatectomy (ralp) is the standard treatment for prostate cancer, due to the benefits of decreased blood loss and length of stay.the procedure involves removing a man's prostate using a minimally invasive robotic approach under the guidance of a surgeon. in order to gain sufficient access, carbon dioxide (co2) is used to fill the surgical space in a process termed insufflation. carbon dioxide is a mainstay in laparoscopic procedures because it is cost-effective, noncombustible and readily excreted via the respiratory system in healthy patients. insufflation with co2, however, has been linked to post-operative referred pain secondary to peritoneal acidosis.this acidosis is suspected to be due to the formation of carbonic acid from the co2 insufflation.peritoneal acidosis, and its associated post-operative referred pain, may not be adequately treated with the current standard pain control regimen.


Eligibility criteria:
inclusion criteria: • male patients ≥18 years of age undergoing robotic-assisted prostatectomy exclusion criteria: * patients with renal insufficiency with serum creatinine \>2.0 mg/dl * patients with renal transplant * patients with pre-existing metabolic acidosis * patients with chronic obstructive pulmonary disease * patients with hepatic disease * patients with central nervous system disorders * patients with hematological disease history * patients with pre-existing electrolyte abnormalities * patients with hypovolemia * patients with lithium or diuretic usage * patients with sulfonamides allergy * patients with american society of anesthesiologists physical status 4 or 5

Keywords: prostatectomy acetazolamide postoperative pain prostate cancer
effect of 8 week plyometric training on injury prevention in domestic cricket players

Conditions: Injury Prevention

Summary: the study aims to find the effectiveness of plyometric training on injury prevention of domestic cricket players. players will be taken from chakwal and a well designed plyometric plan will be implied on them for 8 weeks. after that the results will be compared with the other group who did not get any plyometric training to see the effectiveness of the treatment plan.


Eligibility criteria:
inclusion criteria: * domestic cricket players between 18-25 years. * actively engaged for more than 1 year exclusion criteria: * history of trauma/injury in last month
non exudative amd imaged with ss-oct

Conditions: Dry Macular Degeneration

Summary: the investigators wish to better understand the role of the choriocapillaris (cc) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the cc could prove useful as an anatomic clinical trial endpoint in future drug trials.

this is a longitudinal observational study where the investigators will look at 450 subjects, 200 with intermediate amd in at least one eye, or with amd in one eye, either early or intermediate, and with late amd (exudative) in the other eye, and 250 subjects with nga or ga in at least one eye.

Eligibility criteria:
inclusion criteria: 1. aged 50 and over 2. clinic diagnosis of non-exudative iamd in at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02 mm3 in the absence of ga or nga as diagnosed with oct en face imaging or clinical diagnosis of early or early/intermediate stage amd in one eye in the absence of nga or ga and exudative amd in the other eye or clinical diagnosis of ga or nga secondary to amd that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye which has never been treated with anti-vegf agents 3. willing and able to comply with clinic visits and study-related procedures 4. provide signed informed consent exclusion criteria: a subject who meets any of the following criteria will be excluded from the study: 1. below the age of 50 2. subjects with exudative amd in both eyes 3. eyes with evidence of non-proliferative and proliferative diabetic retinopathy. 4. presence of confounding ocular diagnosis such as myopia \>6d, or other ocular conditions that may cause retinal pigment epithelium atrophy or exudative mnv 5. subjects unable to give informed consent. 6. subjects who are unable to comply with imaging guidelines

Keywords: amd early amd intermediate amd geographic atrophy nascent ga
effect of covid-19 affliction on psychological and mental health among college going students: cross-sectional survey

Conditions: Covid19

Summary: the study aims to study the effects of novel corona virus (covid-19) on the psychological and mental health of college going students. online version of the event impact scale - revised will be used to filled by the students who got afflicted by the novel corona virus (covid-19).

objective : to study the impact on psychological and mental health of covid-19 affliction among college going students methodology: study design: cross-sectional mode of implementation: online surveys population : covid positive college students inclusion criteria: students positive to corona tests exclusion criteria: students negative to corona tests

Eligibility criteria:
inclusion criteria: students positive for covid-19 test - exclusion criteria: students negative for covid-19 test -

Keywords: college students corona covid-19 graduates
the efficacy and safety of pulsed radiofrequency combined with continuous radiofrequency for the trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: trigeminal neuralgia is a very painful condition, and radiofrequency therapy is reserved for patients who are resistant or intolerant to pharmacological therapy. continuous radiofrequency and pulsed radiofrequency both have advantages and disadvantages. recently, studies have found that pulsed radiofrequency combined with low-temperature (\<65 °c) continuous radiofrequency increases the efficacy of the treatment, without leading to a significant increase in complications caused by nerve lesions. however, these reports have some limitations. the investigators plan to conduct a randomized, controlled study to compare the efficacy of applying high-voltage pulsed radiofrequency, with and without low-temperature continuous radiofrequency, to the gasserian ganglion for the treatment of trigeminal neuralgia. the primary outcome will be the effectiveness of the treatment after 12 months which is the percentage of participants with a modified barrow neurological institute pain intensity score between i-iii.


Eligibility criteria:
inclusion criteria: * diagnosed with trigeminal neuralgia according to the international classification of headache disorders, 3rd edition criteria. * aged 18-75 years (inclusive), no sex limitation. * suffering from severe trigeminal neuralgia that cannot be alleviated effectively using conservative medical therapy such as carbamazepine, oxcarbazepine. * numeric rating scale score≥7 before the procedure. * agreed to sign the informed consent form. exclusion criteria: * secondary trigeminal neuralgia such as trigeminal neuralgia attributed to a space-occupying lesion or multiple sclerosis. * infection at the puncture site. * a history of psychiatric disease. * disorder indicated in the results of routine blood tests, hepatic function, renal function, coagulation function, electrocardiogram, or chest x-ray. * serious systemic diseases such as uncontrolled hypertension or diabetes, and cardiac dysfunction (ii-iii of the new york heart association classification). * a history of abuse of narcotics. * a history of receiving continuous radiofrequency to the gasserian ganglion or peripheral branches; glycerol rhizolysis; balloon compression; gamma knife; or any other neuroablative treatments. * a history of receiving microvascular decompression.

Keywords: trigeminal neuralgia pulsed radiofrequency continuous radiofrequency high-voltage pulsed radiofrequency combined with low-temperature continuous radiofrequency
sta-21 topical efficacy on psoriasis

Conditions: Psoriasis

Summary: the clinical assessment of patients with plaque-type psoriasis is performed by open, intrapatient comparison of 0.2% sta-21 with vehicle(vaseline) alone within a 2 week period.

two discrete psoriatic lesions with a similar size (approximately coin-sized) and clinical severity are selected in each patient. clinical assessment of psoriatic lesion severity is performed at the baseline and at 1 and 2 (end of treatment) using the scores of erythema, induration, scaling on a scale of 0-4 by two observers. since sta-21 inhibits stat3 activation, which is essential for disease activity of psoriasis, topical application of 0.2% sta-21 in vaseline should improve psoriasis in two weeks.

Eligibility criteria:
inclusion criteria: * a history of plaque psoriasis for a minimum of 2 years. * in good general health, as evidenced by blood, renal function, and liver function tests conducted before commencing the study. * patients of childbearing age who agreed to continue using birth control for the duration of the study. * men or women between 20 and 80 years old. exclusion criteria: * chronic plaque psoriasis involving \>40% of the body surface. * pustular or generalized erythrodermic psoriasis. * use of medications that might affect the psoriasis during the study * systemic therapy for psoriasis within 60 d of baseline. * uv therapy within 21 d of baseline. * topical therapy within 14 d of baseline. * positive for hiv, hepatitis b, or hepatitis c. * clinically significant laboratory abnormality in blood, renal function, or liver function. * lactating, pregnant, or planning to become pregnant. * participation in another clinical trial in the last 30 d. * unwillingness to comply with the study protocol. * any other condition that in the opinion of the investigators could compromise the study.
an analysis of dermabond vs. non-absorbable sutures in skin closure for brow ptosis procedures

Conditions: Brow Ptosis; Surgical Wound

Summary: the goal of this clinical trial is to compare dermabond with non-absorbable sutures in skin closure after brow ptosis surgery. the main questions it aims to answer are: * if dermabond provides equivalent wound healing compared to conventional non-absorbable skin suture techniques * if dermabond provides equivalent scar appearance compared to conventional non-absorbable suture techniques * if dermabond results in equivalent complication rates compared to conventional non-absorbable suture techniques participants will have be randomly selected to have either dermabond or non-absorbable suture closure methods. scar analysis and both participant and provider surveys will be performed to assess the differences between groups, if any.


Eligibility criteria:
inclusion criteria: * patients undergoing bilateral direct excision brow lift for brow ptosis at the university of kentucky medical center. * patients \> 18 years of age. * patients must be able to follow up at the specified intervals. * patients who are able to give their own informed consent. * health status: variable health status reflective of general population of kentucky. patients will be healthy enough to be seen in an office setting. * all patients will need to be proficient in the english language to understand the scale used for scar assessment exclusion criteria: * patients \ 100 * allergy to dermabond * adults with impaired consent capacity * incarcerated individuals
phase ii trial of preoperative therapy with gefitinib and chemotherapy in patients with erneg breast cancer

Conditions: Breast Cancer

Summary: the aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.


Eligibility criteria:
inclusion criteria: * histologically confirmed oestrogen receptor negative primary breast cancer, tumour stage t2-3, n0-2, m0. eligible for surgery, who performance score 0-1. exclusion criteria: * any prior anticancer therapy including gefitinib (iressa®), epirubicin (farmorubicin™), or cyclophosphamide, distant metastases or bilateral breast cancer, any evidence of clinically active interstitial lung disease , other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ, pregnancy or breastfeeding
effect of optimized peep on mechanical ventilation during robot assisted laparoscopic prostatectomy

Conditions: Prostate Cancer

Summary: steep trendelenburg posture or pneumoperitoneum for surgery causes ventilation problems during surgery, so finding a way to overcome is a challenging task for anesthesiologists. in this study, for patients undergoing robot assisted laparoscopic prostatectomy under general anesthesia, anesthesia is going to perform by applying conventional positive end-expiratory pressure (peep 5cmh2o) or individually determined positive end-expiratory pressure values for each patient using electrical impedance tomography. we plan to compare intraoperative ventilation through arterial blood gas analysis to find out the way to improve intraoperative ventilation.


Eligibility criteria:
inclusion criteria: 1. 20 - 70 years of age who are scheduled for robotic assisted laparoscopic prostatectomy at the department of urology, gangnam severance hospital, 2. asa-ps (american society of anesthesiology body rating) i-ili, 3. patients with a bmi of 35 kg/m2 or less exclusion criteria: 1. patients with lung disease 2. bmi \>35kg/m2 3. patients for whom positive end-tidal pressure cannot be applied (large bullae, severe cardiac disease) 4. patient refusal
azithromycin for uncomplicated severe acute malnutrition in burkina faso (pilot)

Conditions: Uncomplicated Severe Acute Malnutrition

Summary: this pilot study is a randomized controlled trial designed to test the effect of the administration of adjunctive azithromycin in conjunction with standard outpatient treatment for uncomplicated severe acute malnutrition (sam) in children aged 6-59 months. children presenting to nutritional programs in burkina faso who meet eligibility criteria will be randomized to a single dose of oral azithromycin or a 7-day course of amoxicillin (standard of care) upon admission into the program. all enrolled children will receive ready-to-use therapeutic foods (rutf). enrolled children will be followed at each weekly clinic follow-up visit up to 8 weeks following admission. data on anthropometric indicators, vital status, and adverse events will be collected during follow-up. nutritional recovery over the 8-week study period will be compared by arm.


Eligibility criteria:
inclusion criteria: * age 6-59 months * whz \<-3 sd or muac \<115 mm * no nutritional edema * able and willing to participate in full 8-week study * has not been admitted to a nutritional program for the treatment of sam in the 3 preceeding months * no antibiotic use in past 7 days * no clinical complications requiring inpatient treatment (except for routine admission for children \<6 months) * no congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of sam treatment benefit (such as cerebral palsy, down syndrome, congenital heart disease, cleft lip/palate, etc) * no allergy to macrolides/azalides * sufficient appetite according to a feeding test with ready-to-use therapeutic food (rutf) * appropriate consent from at least one parent or guardian exclusion criteria: * age \ 59 months * whz ≥-3 sd or muac ≥115 mm * nutritional edema * not able or willing to participate in full 8-week study * admission to a nutritional program for the treatment of sam in the 3 preceeding months * antibiotic use in past 7 days * clinical complications requiring inpatient treatment * congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of sam treatment benefit (such as cerebral palsy, down syndrome, congenital heart disease, cleft lip/palate, etc) * allergy to macrolides/azalides * insufficient appetite according to a feeding test with ready-to-use therapeutic food (rutf) * parent or guardian refuses to provide consent
teenagers after london terrorist attack

Conditions: Adolescent Development; Post Traumatic Stress Disorder; Terrorism

Summary: * context: since march 2012, several terrorist attacks have been perpetrated in france (toulouse, montauban, paris, nice ...). in march 2017, 53 french teenagers were victims in a terrorist attack in london (westminster bridge). * main goal = to estimate the psycho-traumatic impact and to describe cares and management of high school students, victims of the terrorist attack in london on 2017, march the 22nd. * 3 secondary objectives: 1) clinical (occurrence of post traumatic stress disorders or other disorders); 2) epidemiological (risk factors for developing disorders, avoiding care); 3) preventive and therapeutic.

inclusion criterion: 53 teenagers of saint-joseph high school (concarneau, france) directly exposed to the terrorist attack. methodology: self questionnaires and heterogenous questionnaires; descriptive statistics (means +/- standard deviations; search for a significant difference according to traumatic symptomatology)

Eligibility criteria:
inclusion criteria: * 53 teenagers, from concarneau (france) high school, directly exposed from london terrorist attack (22.03.2017). exclusion criteria: * all persons not directly exposed; * relatives of teenagers; * 3 physically injured teenagers.

Keywords: adolescent post traumatic stress disorder terrorist attack
study of postoperative concurrent chemo-radiation with capecitabine in elderly rectal cancer patients

Conditions: Rectal Neoplasms

Summary: the purpose of this study is to seek the proper dose of capecitabine in post-operative concurrent chemotherapy for stage ii/iii elderly rectal cancer patients receiving radical surgery, and evaluate the toleration of this modality in such patients.

for those "younger" locally advanced (stage ii/iii) rectal cancer patients (usually means patients less than 70), it is suggested that after radical surgery, patients should receive concurrent chemo-radiation. capecitabine is a widely used chemotherapy medicine under such condition. based on experience, the investigators think this modality can also be tolerated by patients over 70, and will increase local control rate as which has been proved in younger ones. as the first step to test this hypothesis, we designed this phase i study to seek the proper dose of capecitabine, a widely used oral chemotherapy medicine, in postoperative concurrent chemo-radiation for stage ii/iii rectal cancer patients over 70, and to evaluate the safety of this modality in this group of patients.

Eligibility criteria:
inclusion criteria: * rectal adenocarcinoma, pathological stage ii/iii(t3-4 or n+, uicc 2002), radical surgery received. * interval between surgery and enrollment no less than two week and no more than 3 months. * kps status no less than 70; life expectancy no less than 6 months. * without life-threatening complications, such as severe hypertension, coronary heart disease, cerebral vascular disease, uncontrolled diabetes, etc. * without severe drug allergy history. * hemoglobin \>= 100g/l, white blood cell \>= 3.5\*10e9/l, neutrophil \>= 1.5\*10e9/l, platelet \>= 100\*10e9/l. * creatin \<= 1.5\* uln(upper limit of normal), total bilirubin \<= 2.5 uln, ast and ast \<= 2.5\* uln, akp \<= 2.5\*uln * do not receive chemotherapy before six months from enrollment. * no previously pelvic irradiation history * informed consent signed exclusion criteria: * other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma * allergy history to thymidine phosphorylase * previous pelvic irradiation history * receiving adjuvant chemotherapy in six months before enrollment * active infection existed * severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( plasma glucose concentrations in any time of a day≥11.1mmol/l）, severe cardiac arrhythmia， etc. * life expectancy less than 6 months * estimated cannot finish treatment * attend other clinical trials in four weeks before enrollment * receive other anti-cancer treatment currently * other conditions which regarded illegal by censors with full reasons. for example, some conditions may conflict from the protocol.

Keywords: rectal neoplasms aged radiotherapy drug therapy dose-escalation capecitabine
study of aro-dm1 in subjects with type 1 myotonic dystrophy

Conditions: Myotonic Dystrophy 1

Summary: this is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of single and multiple ascending doses of aro-dm1 compared to placebo in male and female subjects with type 1 myotonic dystrophy (dm1). participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (part 1) or multiple (part 2) doses of aro-dm1 or placebo.


Eligibility criteria:
inclusion criteria: * genetically confirmed diagnosis of dm1 * clinician-assessed signs of dm1 including clinically apparent myotonia * onset of dm1 symptoms occurred after the age of 12 years * walk for at least 10 meters independently at screening * subjects of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. subjects must not donate sperm or eggs during the study and for at least 90 days following the end of study or last dose of study drug whichever is later. exclusion criteria: * inadequately controlled diabetes * confirmed diagnosis of congenital dm1 * uncontrolled hypertension * history of thromboembolic events * history of tibialis anterior (ta) biopsy within 3 months of day 1 or planning to undergo ta biopsies during the study period * clinically significant cardiac, liver or renal disease * hiv infection (seropositive) at screening * seropositive for hepatitis b (hbv) or hepatitis c (hcv) at screening * untreated or poorly controlled epilepsy * treatment with anti-myotonia medication within a period of 5 half-lives of the medication prior to screening. * abnormal coagulation parameters at screening including platelet count, international normalized ratio (inr), prothrombin time, and activated partial thromboplastin time (aptt) * history or presence of any of the following: hypercoagulable state, nephrotic range proteinuria, antiphospholipid antibody syndrome or myeloproliferative diseases, inability to ambulate, use of hormone-based contraceptives and peri/post- menopausal hormone replacement therapy ≤ 16 weeks prior to day 1 note: additional inclusion/exclusion criteria may apply per protocol